Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood marker reveal how rehabilitation affects axial spondyloarthritis?

NCT ID NCT07821541

Knowledge-focused Sponsor: Giresun University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers at Giresun University are studying whether a blood protein called calprotectin changes in people with axial spondyloarthritis who complete a four-week pulmonary rehabilitation program. Thirty patients aged 25 to 65 will take part. The team will measure calprotectin alongside other inflammation markers, lung function, disease activity scores, and quality-of-life questionnaires before and after rehabilitation to see how these measures relate to each other.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a four-week pulmonary rehabilitation program
What this could lead to
If calprotectin tracks with disease activity, doctors may gain a simple blood marker to follow axial spondyloarthritis over time.
What could go wrong
The study is small, with 30 participants, and it only observes changes during rehabilitation. It cannot prove that rehabilitation causes any shift in calprotectin or that the marker predicts long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Aug 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of 30 voluntary patients aged between 25 and 65 years, diagnosed with axial spondyloarthritis according to the ASAS classification criteria, and enrolled in a pulmonary rehabilitation program at the Cardiopulmonary Rehabilitation Unit of the Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Giresun University, between April 2025 and April 2025, were included in the study.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Classification as axial spondyloarthritis according to the 2009 ASAS (Assessment of SpondyloArthritis International Society) criteria * Age between 25 and 65 years * Both male and female patients * Ability to perform pulmonary function tests (PFTs) with full cooperation Exclusion Criteria: * Change in antirheumatic medication or dosage within the last 3 months * Engagement in regular physical activity within the last 3 months * History of unstable angina pectoris, cardiac arrhythmias, or myocardial infarction within the last 3 months * Presence of any orthopedic, neurological, or mental disorder that could affect exercise performance * History of pulmonary disease (asthma, COPD, atelectasis, etc.) * Active malignancy and/or history of malignancy within the last 5 years * History of syncope or exercise-induced arrhythmia * Current pregnancy or planning pregnancy in the near future * History of major surgery within the last 6 months * Use of assistive devices for ambulation or presence of orthopedic joint prosthesis * Patients with total spinal ankylosis * Presence of a known additional rheumatologic disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Axial spondylarthritis (axspa) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Axial spondylarthritis (axspa)

Contacts and locations

Locations

  • Giresun University Faculty of Medicine

    Giresun, 28200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.